PL-3994 intravenous
/ Palatin Technologies
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 14, 2021
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
(clinicaltrials.gov)
- P2; N=55; Recruiting; Sponsor: Palatin Technologies; Trial completion date: Nov 2021 ➔ Mar 2023; Trial primary completion date: Oct 2021 ➔ Mar 2022
Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
September 21, 2021
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
(clinicaltrials.gov)
- P2; N=55; Recruiting; Sponsor: Palatin Technologies; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure
March 23, 2020
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
(clinicaltrials.gov)
- P2; N=55; Not yet recruiting; Sponsor: Palatin Technologies
Clinical • New P2 trial
1 to 3
Of
3
Go to page
1